J&J to scout early-stage deals in 4 biotech hotspots

Johnson & Johnson never has made much of a mark in the sphere of early drug development. But now J&J ($JNJ) is thinking globally and acting locally, creating a plan to become a more prominent player in the field of translational medicine by setting up deal teams in four biotech hotspots around the world. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.